Min-Hui Xu

Min-Hui Xu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2019 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
WYWei Yang
Wei Yang
PWPeng-Fei Wu
Peng-Fei Wu
JMJian-Xing Ma
Jian-Xing Ma
MLMao-Jun Liao
Mao-Jun Liao
XWXu-Hui Wang
Xu-Hui Wang
LYLiang Yi
Liang Yi
High aggressiveness is a hallmark of glioblastoma and predicts poor prognosis of patients with glioblastoma. The expression level of sortilin has been preliminarily reported to be elevated in high-grade glioma; however, the potential significance of sortilin in glioblastoma progression has not been elucidated. In this study, we investigated the oncogenic effect of sortilin in glioblastoma. Increased levels of sortilin were noted in the mesenchymal subtype of glioblastoma and highly aggressive subtypes of glioblastoma tissues and cell lines. In addition, high levels of sortilin predicted poor prognoses in patients with glioblastoma. Sortilin knockdown or inhibition with AF38469 (an orally bioavailable inhibitor of sortilin) significantly suppressed migration and invasion by inhibiting EMT-like mesenchymal transition in glioblastoma cells. Furthermore, we proved that sortilin promoted cell invasion mainly via Glycogen synthase kinase 3 beta (GSK-3β)/β-catenin/Twist-induced EMT-like mesenchymal transition in glioblastoma. Taken together, our results demonstrate a critical role of sortilin in glioblastoma invasion and EMT-like mesenchymal transition, indicating that sortilin contributes to glioblastoma progression. These data also highlight the dramatic antitumor effects of AF38469 in glioblastoma, suggesting that AF38469 is a potentially powerful antitumor agent for sortilin-overexpressing human glioblastoma.

17 July 2017 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
QOQing Ouyang
Qing Ouyang
JZJi Zhou
Ji Zhou
WYWei Yang
Wei Yang
HCHongjuan Cui
Hongjuan Cui
MXMin-Hui Xu
Min-Hui Xu
LYLiang Yi
Liang Yi

1 September 2018 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
QOQing Ou-Yang
Qing Ou-Yang
BLBing Li
Bing Li
MXMin-Hui Xu
Min-Hui Xu
HLHong Liang
Hong Liang

14 July 2015 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
QOQing Ouyang
Qing Ouyang
GCGang Chen
Gang Chen
JZJi Zhou
Ji Zhou
LLLei Li
Lei Li
ZDZhen Dong
Zhen Dong
LYLiang Yi
Liang Yi
Neurotensin (NTS) and its primary receptor NTSR1 are implicated in cancer progression. Aberrant expression of NTS/NTSR1 contributes to the proliferation of glioblastoma cells; however, the mechanism is not fully understood. Microarray and real-time PCR were performed to identify the NTS-regulated micro (mi)RNAs. The targets of the miRNAs were identified by luciferase assays and immunoblot analysis. The c-Myc binding sites in the miR-29b-1 and cyclin-dependent kinase (CDK)4 promoters were identified through chromatin immunoprecipitation assay. Cell proliferation was evaluated by Cell Counting Kit-8 assay and flow cytometry analysis. An orthotopic xenograft model demonstrated the role of NTS/NTSR1 and miRNAs in glioblastoma growth in vivo. Pharmacological inhibition or small interfering NTSR1 treatment blocked glioblastoma cell cycle progression in the G1 phase with a concomitantly decreased expression of CDK6, CDK4, and c-Myc. Knockdown of NTSR1 increased the expression of miR-29b-1 and miR-129-3p, which were responsible for the decreased CDK6 expression. NTS/NTSR1 signaling activated the transcription factor c-Myc in U87 cells, leading to increased CDK4 expression and repressed miR-29b-1 expression. Knockdown of NTSR1 decreased the glioblastoma growth in vivo and significantly prolonged the survival time of the tumor-bearing mice, an effect that can be largely reversed by antagomir. Our study showed a novel regulatory mechanism of NTS/NTSR1, an upstream signaling of miRNAs and c-Myc, in glioblastoma progression. The inhibition of the NTSR1 function or the upregulation of miR-29b-1 and miR-129-3p expression impaired glioma cell proliferation. These results suggested that the NTS/NTSR1/c-Myc/miRNA axis may be a potential therapeutic target for glioblastoma therapy.

20 July 2015 in International Journal of Neuroscience
Verified
Journal Article
Closed access
PDF file
QOQing Ouyang
Qing Ouyang
LXLunshan Xu
Lunshan Xu
HCHongjuan Cui
Hongjuan Cui
MXMin-Hui Xu
Min-Hui Xu
LYLiang Yi
Liang Yi
The control of malignant glioma cell cycle by microRNAs (miRNAs) is well established. The deregulation of miRNAs in glioma may contribute to tumor proliferation by directly targeting the critical cell-cycle regulators. Tumor suppressive miRNAs inhibit cell cycle through repressing the expression of positive cell-cycle regulators. However, oncogenic miRNAs promote the cell-cycle progression by targeting cell-cycle negative regulators. Recent studies have identified that transcription factors had involved in the expression of miRNAs. Transcription factors and miRNAs are implicated in regulatory network of glioma cell cycle, the deregulation of these transcription factors might be a cause of the deregulation of miRNAs. Abnormal versions of miRNAs have been implicated in the cell cycle of glioma. Based on those, miRNAs are excellent biomarker candidates and potential targets for therapeutic intervention in glioma.

19 April 2019 in Neurochemical Research
Verified
Journal Article
Closed access
PDF file
XWXuhui Wang
Xuhui Wang
HWHong Wang
Hong Wang
TZTao Zhang
Tao Zhang
MHMeng He
Meng He
HLHong Liang
Hong Liang
MXMin-Hui Xu
Min-Hui Xu